Oncopeptides AB (publ) (STO:ONCO)

Oncopeptides AB Statistics

Total Valuation

Oncopeptides AB has a market cap or net worth of SEK 646.29 million. The enterprise value is 571.94 million.

Market Cap	646.29M
Enterprise Value	571.94M

Important Dates

The last earnings date was Tuesday, April 28, 2026.

Earnings Date	Apr 28, 2026
Ex-Dividend Date	n/a

Share Statistics

Oncopeptides AB has 395.29 million shares outstanding.

Current Share Class	381.15M
Shares Outstanding	395.29M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.46%
Owned by Institutions (%)	10.04%
Float	379.33M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	7.76
PB Ratio	8.42
P/TBV Ratio	8.42
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-2.59
EV / Sales	6.87
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.55, with a Debt / Equity ratio of 1.70.

Current Ratio	4.55
Quick Ratio	4.38
Debt / Equity	1.70
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-14.07

Financial Efficiency

Return on equity (ROE) is -623.33% and return on invested capital (ROIC) is -75.92%.

Return on Equity (ROE)	-623.33%
Return on Assets (ROA)	-57.08%
Return on Invested Capital (ROIC)	-75.92%
Return on Capital Employed (ROCE)	-94.32%
Weighted Average Cost of Capital (WACC)	-1.50%
Revenue Per Employee	1.11M
Profits Per Employee	-2.95M
Employee Count	75
Asset Turnover	0.37
Inventory Turnover	0.37

Taxes

In the past 12 months, Oncopeptides AB has paid 1.49 million in taxes.

Income Tax	1.49M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -19.06% in the last 52 weeks. The beta is -1.42, so Oncopeptides AB's price volatility has been lower than the market average.

Beta (5Y)	-1.42
52-Week Price Change	-19.06%
50-Day Moving Average	1.46
200-Day Moving Average	3.69
Relative Strength Index (RSI)	54.30
Average Volume (20 Days)	10,734,046

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Oncopeptides AB had revenue of SEK 83.24 million and -221.10 million in losses.

Revenue	83.24M
Gross Profit	80.38M
Operating Income	-203.34M
Pretax Income	-219.61M
Net Income	-221.10M
EBITDA	-201.11M
EBIT	-203.34M
Earnings Per Share (EPS)	n/a

Balance Sheet

The company has 205.15 million in cash and 130.80 million in debt, with a net cash position of 74.35 million or 0.19 per share.

Cash & Cash Equivalents	205.15M
Total Debt	130.80M
Net Cash	74.35M
Net Cash Per Share	0.19
Equity (Book Value)	76.79M
Book Value Per Share	n/a
Working Capital	200.04M

Cash Flow

Operating Cash Flow	-200.16M
Capital Expenditures	n/a
Depreciation & Amortization	2.23M
Net Borrowing	-8.16M
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is 96.57%, with operating and profit margins of -244.29% and -265.63%.

Gross Margin	96.57%
Operating Margin	-244.29%
Pretax Margin	-263.84%
Profit Margin	-265.63%
EBITDA Margin	-241.61%
EBIT Margin	-244.29%
FCF Margin	n/a

Dividends & Yields

Oncopeptides AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-34.21%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	4